2/1
07:03 pm
rprx
Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain [Yahoo! Finance]
Low
Report
Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain [Yahoo! Finance]
1/30
06:01 am
rprx
Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
Low
Report
Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
1/28
10:48 am
rprx
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! Finance]
Low
Report
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! Finance]
1/27
07:19 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
1/24
07:06 am
rprx
Jim Cramer on Royalty Pharma: “It's a Terrific Company” [Yahoo! Finance]
Low
Report
Jim Cramer on Royalty Pharma: “It's a Terrific Company” [Yahoo! Finance]
1/22
08:11 pm
rprx
Lightning Round: Coherent is a winner, says Jim Cramer [CNBC]
Low
Report
Lightning Round: Coherent is a winner, says Jim Cramer [CNBC]
1/20
04:15 pm
rprx
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Low
Report
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
1/14
08:18 am
rprx
Teva Is No Longer A Turnaround Story, It's A Growth One [Seeking Alpha]
Low
Report
Teva Is No Longer A Turnaround Story, It's A Growth One [Seeking Alpha]
1/13
06:33 am
rprx
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]
Low
Report
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]
1/12
07:15 am
rprx
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/12
01:38 am
rprx
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]
Low
Report
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]
1/11
05:15 pm
rprx
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Low
Report
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
1/9
08:30 am
rprx
Royalty Pharma Announces Dividend Increase
Low
Report
Royalty Pharma Announces Dividend Increase
1/8
11:51 pm
rprx
Is Royalty Pharma (RPRX) Pricing Reflect Its Strong 1 Year Share Price Performance [Yahoo! Finance]
Low
Report
Is Royalty Pharma (RPRX) Pricing Reflect Its Strong 1 Year Share Price Performance [Yahoo! Finance]
12/29
08:21 pm
rprx
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones [Yahoo! Finance]
Low
Report
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones [Yahoo! Finance]
12/29
04:40 pm
rprx
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Low
Report
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
12/16
08:08 am
rprx
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]
Medium
Report
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]
12/16
07:15 am
rprx
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Low
Report
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
12/11
02:10 pm
rprx
Royalty Pharma (NASDAQ:RPRX) was given a new $45.00 price target on by analysts at Leerink Partners.
Low
Report
Royalty Pharma (NASDAQ:RPRX) was given a new $45.00 price target on by analysts at Leerink Partners.
12/11
11:48 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its price target raised by analysts at TD Cowen from $42.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its price target raised by analysts at TD Cowen from $42.00 to $45.00. They now have a "buy" rating on the stock.
12/11
10:04 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/5
06:16 am
rprx
Denali makes $275m funding agreement with Royalty Pharma [Yahoo! Finance]
Low
Report
Denali makes $275m funding agreement with Royalty Pharma [Yahoo! Finance]
12/5
05:43 am
rprx
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement [Yahoo! Finance]
Low
Report
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement [Yahoo! Finance]
12/4
07:10 am
rprx
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
Low
Report
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
12/3
06:18 pm
rprx
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Medium
Report
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]